ReviewJournal of thrombosis and thrombolysis2022
Arterial and venous involvement in Behçet's syndrome: a narrative review.
Review in Journal of thrombosis and thrombolysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- A systematic review and meta-analysis of the association between the D-dimer and rheumatic diseases.Immunity, inflammation and disease · 2024Pooled it
- Subclinical atherosclerosis in Behcet's disease and its inverse relation to azathioprine use: an updated meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Concomitant Budd-Chiari syndrome and coronary artery pseudoaneurysm in Behçet's disease: A case report.The international journal of cardiovascular imaging · 2026Article
- Superficial Venous Thrombosis in Non-Varicose Veins: A Narrative Review.Journal of clinical medicine · 2026Review
- From inflammation to rupture: advances in the pathogenesis of pseudoaneurysm formation in Vascular Behçet's Disease.Frontiers in immunology · 2026Review
- Intestinal necrosis in a patient with Behçet's disease and infective endocarditis: a case report.Frontiers in cardiovascular medicine · 2026Article
- Non-pulmonary arterial involvement in Behçet's disease: a multicenter retrospective case series.Turkish journal of medical sciences · 2026Observational
- Vasculitis associated with VEXAS syndrome.Rheumatology (Oxford, England) · 2025Article
- Patient with Behçet Syndrome with Subaortic Pseudoaneurysm Who Underwent the Bentall Operation Showed Improvement after Medical Treatment.Yonsei medical journal · 2025Article
- Hughes-Stovin Syndrome: A Rare Cause of Pulmonary Artery Aneurysm and Thrombosis-A Case Report.International journal of rheumatic diseases · 2025Article
- Impact of SARS-CoV-2 infection therapies on the risk of venous thromboembolism and cardiovascular events from the SEMI-COVID-19 Registry.Scientific reports · 2025Observational
- Widespread venous thrombosis: Unveiling a complex case of Behçet's disease with a literature perspective.Open medicine (Warsaw, Poland) · 2025Article
- Thrombosis in vasculitis: An updated review of etiology, pathophysiology, and treatment.Heliyon · 2024Review
- Treatment Options in Pediatric Behçet's Disease.Paediatric drugs · 2023Review
- Behçet's Disease: A Radiological Review of Vascular and Parenchymal Pulmonary Involvement.Diagnostics (Basel, Switzerland) · 2022Review
- Case report and analysis: Behçet's disease with lower extremity vein thrombosis and pseudoaneurysm.Frontiers in immunology · 2022Article
- Serum Endocan Levels and Subclinical Atherosclerosis in Behçet's Syndrome.International journal of general medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Behçet syndrome (BS) is a unique type of vasculitis that affects veins and arteries of all sizes, leading to recurrent vascular events, mostly venous thrombosis. The prevalence of venous thromboembolism in BS patients ranges between 15 and 40%. Thrombosis is usually an early manifestation leading to diagnosis of BS in up to 40% of patients. BS is per se a model of inflammation-induced thrombosis. The primary autoimmune response activates lymphocytes that in turn produce a cytokine cascade that activates neutrophils, which modify the secondary structure of fibrinogen making it less susceptible to plasmin-induced lysis. This leads to endothelial dysfunction, platelet activation and overexpression of tissue factor leading to inflammatory thrombi, usually attached to the wall. The pathogenesis of thrombosis is especially relevant to direct the specific treatment, that is based on immunosuppression rather than anticoagulation. Superficial vein thrombosis (SVT) and deep vein thrombosis (DVT) are the most common form of thrombosis in BS, but thrombosis in atypical sites (cava vein, suprahepatic veins, intracardiac thrombus) and arterial involvement can also occur. We assessed the latest update of the European League Against Rheumatism recommendations for the management of BS. Vascular Behçet treatment is usually based of immunosuppressants, and the role of anticoagulation remains controversial. The use of interventional and surgical procedures should be carefully evaluated, due to the risk of triggering a vascular pathergy phenomenon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.